Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

552
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
552
Nociception01:44

Nociception

27.8K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
27.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Huachansu triggers mitochondrial apoptosis and ER stress to inhibit hepatocellular carcinoma progression.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2026
Same author

Topology-Driven Activation of the GLP-1 Receptor Promotes Adipose Tissue Browning.

Protein & cell·2026
Same author

RND3 Enhances Cardiac Glucose Metabolism Through Inhibiting ACAT1-Dependent PDHA1 Acetylation and Protects Against Ischemia-Reperfusion Injury.

Circulation·2026
Same author

Dual-Stimulus Chiroptical Switch of Tetrastable [3]Rotaxanes.

Organic letters·2026
Same author

Unveiling medication patterns in traditional Chinese medicine for the prevention of colorectal cancer recurrence: from potential combinations to validation of components and targets.

Chinese medicine·2026
Same author

Drug-Coated Balloons Versus Drug-Eluting Stents for Patients With Long De Novo Coronary Artery Lesions: Insights From the REC-CAGEFREE I Trial.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

Related Experiment Video

Updated: Jun 13, 2025

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.5K

PSD-95 Protein: A Promising Therapeutic Target in Chronic Pain.

Lulin Ma1,2, Dongdong Sun3, Song Wen4,5

  • 1Department of Pain Medicine, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, China.

Molecular Neurobiology
|September 16, 2024
PubMed
Summary

Postsynaptic density (PSD)-95 protein is crucial in chronic pain development. Inhibiting PSD-95 and related proteins offers a promising new therapeutic target for managing chronic pain effectively.

Keywords:
5-HT2ARAMPARCaMKIIChronic painGluN2BPSD-95nNOS

More Related Videos

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.1K
Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
07:12

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats

Published on: January 21, 2020

7.6K

Related Experiment Videos

Last Updated: Jun 13, 2025

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.5K
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

48.1K
Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
07:12

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats

Published on: January 21, 2020

7.6K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain Research

Background:

  • Chronic pain significantly impacts patient quality of life and presents a major public health challenge.
  • Current treatments like opioids and NSAIDs have limitations due to side effects, necessitating novel therapeutic targets.
  • Postsynaptic density (PSD)-95 protein is implicated in the development and persistence of chronic pain.

Purpose of the Study:

  • To explore the role of Postsynaptic density (PSD)-95 protein in chronic pain.
  • To identify PSD-95 and associated proteins as potential therapeutic targets for chronic pain.
  • To review existing evidence on drugs targeting PSD-95 for pain management.

Main Methods:

  • Literature review of studies investigating Postsynaptic density (PSD)-95 protein in chronic pain models.
  • Analysis of research on the interaction of PSD-95 with other key proteins involved in pain signaling.
  • Examination of preclinical and clinical data on drugs targeting PSD-95.

Main Results:

  • Over-expression of Postsynaptic density (PSD)-95 protein is closely linked to chronic pain.
  • PSD-95 interacts with critical proteins including NMDA receptor (NMDAR) subunit 2B (GluN2B), AMPA receptor (AMPAR), calmodulin-dependent protein kinase II (CaMKII), 5-hydroxytryptamine 2A receptor (5-HT2AR), and neuronal nitric oxide synthase (nNOS).
  • Drugs designed to inhibit PSD-95 expression and its interactions have shown significant efficacy in treating chronic pain.

Conclusions:

  • Postsynaptic density (PSD)-95 protein is a key player in the pathophysiology of chronic pain.
  • Targeting PSD-95 and its interacting proteins represents a promising strategy for developing new, effective chronic pain therapies.
  • Further research is warranted to fully elucidate the therapeutic potential of targeting the PSD-95 pathway.